ArticleJournal of assisted reproduction and genetics2025
Embryo division timings and top-quality embryo rates in GnRH-Antagonist ICSI cycles: a comparison of hCG and dual trigger methods.
Article in Journal of assisted reproduction and genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Non-Linear Association Between Serum Estradiol Decline and Clinical Outcomes in IVF/ICSI Cycles: A Retrospective Cohort Study.International journal of women's health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the impact of trigger types in Gonadotropin-releasing hormone (GnRH) antagonist IVF-ICSI cycles on embryo morphokinetics and top-quality embryo production.
methodsRetrospective cohort study of GnRH-antagonist IVF-ICSI cycles from July 2013 to December 2022. Embryo morphokinetics, top-quality embryo rates, and outcomes were compared between hCG and dual trigger (GnRH-agonist and hCG). Matching was based on age, BMI, and number of aspirated oocytes. Dual trigger consisted of Decapeptyl 0.2 mg and Ovitrelle 250 mcg, administered simultaneously. Embryo development was monitored with Embryoscope Time-lapse, and top-quality embryos were identified using an in-house model based on known implantation outcomes.
resultsOf 1224 women, 269 matched pairs were analyzed, including 792 embryos in the dual trigger group and 758 in the hCG group. Most demographic and clinical parameters were comparable. Significant differences included higher basal FSH (8.1 ± 2.7 vs. 7.5 ± 2.5 IU/mL, P = 0.024) and total FSH dose (2991.9 ± 1048.5 vs. 2277.1 ± 1070.2, P < 0.001) in the dual trigger group. Embryo morphokinetics showed no significant differences, except for slightly longer time to fourth cleavage (t4: 40.4 ± 6.0 vs. 39.8 ± 4.5 h, P = 0.032) and synchrony of the second division (S2: 1.3 ± 2.7 vs. 1.0 ± 1.8 h, P = 0.008) in the dual trigger group. Top-quality embryo rates and clinical outcomes, including pregnancy, implantation, miscarriage, and live birth, were comparable between groups, with a later embryo transfer day in the dual trigger group (3.5 ± 1.3 vs. 3.2 ± 1.1 days, P = 0.011).
conclusionsDual triggering in GnRH-antagonist ICSI cycles did not improve most morphokinetic parameters, top-quality embryo rates, or clinical outcomes over hCG alone, suggesting limited benefit in general populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.